1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
AMENDMENT NO. 1
TO
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
For Quarter Ended: February 24, 1996
-----------------
Commission File No: 0-10824
-------
GENOME THERAPEUTICS CORPORATION
-------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
MASSACHUSETTS 04-2297484
------------- ----------
(STATE OR OTHER JURISDICTION (I.R.S. EMPLOYER IDENTIFICATION
OF INCORPORATION OR ORGANIZATION) NO.)
100 BEAVER STREET; WALTHAM, MASSACHUSETTS 02154
- --- ------ ------ ------- ------------- -----
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER: (617) 893-5007
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
COMMON STOCK 16,899,090
- ------ ----- -------------------------
$.10 PAR VALUE Outstanding April 8, 1996
---- --- -----
SERIES B RESTRICTED STOCK 57,512
- ------ - ---------- ----- -------------------------
$.10 PAR VALUE Outstanding April 8, 1996
---- --- -----
2
This amendment reflects the incorporation of Insert A - Tabulation of Matters
Voted on by Security Holders into Part II, Item 4 of Form 10Q for period ended
February 24, 1996.
3
INSERT A
The company's Special Meeting in lieu of an Annual Meeting was held on
February 16, 1996. At the meeting, shareholders took the following actions:
1) Election of Directors
Name of Nominee Shares Voting
--------------- -------------
FOR WITHHOLD AUTHORITY
Robert J. Hennessey 11,483,593 27,142
Orrie M. Friedman 11,473,673 37,062
Philip J. Leder 11,488,093 22,642
Lawrence Levy 11,479,043 31,692
Donald J. McCarren 11,478,893 34,842
Steven M. Rauscher 11,476,093 34,642
2) To approve 1995 Stock Option Plan
FOR AGAINST ABSTAIN NO VOTING
6,922,764 718,771 77,508 3,791,692
3) To approve a grant of stock option to Robert J. Hennessey
FOR AGAINST ABSTAIN NO VOTING
4,927,609 2,957,466 75,508 3,550,152
4) To approve a grant of stock option to Dr. Philip Leder
FOR AGAINST ABSTAIN NO VOTING
7,419,276 467,599 73,708 3,550,152
5) To approve a grant of stock option to Lawrence Levy
FOR AGAINST ABSTAIN NO VOTING
7,403,391 480,784 76,408 3,550,152
4
6) To approve a grant of stock option to Donald J. McCarren
FOR AGAINST ABSTAIN NO VOTING
7,407,566 478,009 75,008 3,550,152
7) To approve a grant of stock option to Steven M. Rauscher
FOR AGAINST ABSTAIN NO VOTING
7,407,164 476,934 76,485 3,550,152
8) To ratify the selection of Arthur Andersen LLP as the company's
auditors for the fiscal year ending August 31, 1996.
FOR AGAINST ABSTAIN NO VOTING
11,434,608 42,787 33,340 0
5
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has caused this report to be signed on its behalf by the undersigned
thereunto duly authorized who also serves in the capacity of principal financial
officer.
Genome Therapeutics Corporation
/s/ Fenel M. Eloi
----------------------
Fenel M. Eloi
(Principal Financial Officer)
Date: April 22, 1996